- Home
- GF vs ELDN Comparison
GF vs ELDN Comparison
Compare GF & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- ELDN
- Stock Information
- Founded
- GF 1990
- ELDN 2004
- Country
- GF Germany
- ELDN United States
- Employees
- GF N/A
- ELDN N/A
- Industry
- GF Investment Managers
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- ELDN Health Care
- Exchange
- GF Nasdaq
- ELDN Nasdaq
- Market Cap
- GF 188.5M
- ELDN 202.4M
- IPO Year
- GF N/A
- ELDN N/A
- Fundamental
- Price
- GF $11.72
- ELDN $2.59
- Analyst Decision
- GF
- ELDN Strong Buy
- Analyst Count
- GF 0
- ELDN 2
- Target Price
- GF N/A
- ELDN $12.50
- AVG Volume (30 Days)
- GF 28.1K
- ELDN 936.8K
- Earning Date
- GF 01-01-0001
- ELDN 08-14-2025
- Dividend Yield
- GF 0.82%
- ELDN N/A
- EPS Growth
- GF N/A
- ELDN N/A
- EPS
- GF N/A
- ELDN 0.21
- Revenue
- GF N/A
- ELDN N/A
- Revenue This Year
- GF N/A
- ELDN N/A
- Revenue Next Year
- GF N/A
- ELDN N/A
- P/E Ratio
- GF N/A
- ELDN $12.40
- Revenue Growth
- GF N/A
- ELDN N/A
- 52 Week Low
- GF $7.38
- ELDN $2.38
- 52 Week High
- GF $9.41
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- GF 47.07
- ELDN 38.24
- Support Level
- GF $11.65
- ELDN $2.53
- Resistance Level
- GF $11.90
- ELDN $2.70
- Average True Range (ATR)
- GF 0.14
- ELDN 0.11
- MACD
- GF -0.01
- ELDN 0.01
- Stochastic Oscillator
- GF 42.50
- ELDN 34.04
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.